Guardant Health, Inc. (GH) stock
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$145.14+1.86 (+1.30%)
Close on Nov 18, 2026Market cap $19.48BP/E –Yield –
Guardant Health operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Guardant Health's operating income for the twelve months ending Jun 30, 2026 was -$470.26M. For fiscal 2025 it was -$437.25M. The highest annual figure on record is -$43.85M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$437.25M | – |
| FY2024 | Dec 31, 2024 | -$443.59M | – |
| FY2023 | Dec 31, 2023 | -$564.73M | – |
| FY2022 | Dec 31, 2022 | -$544.38M | – |
| FY2021 | Dec 31, 2021 | -$411.00M | – |
| FY2020 | Dec 31, 2020 | -$254.95M | – |
| FY2019 | Dec 31, 2019 | -$82.37M | – |
| FY2018 | Dec 31, 2018 | -$92.94M | – |
| FY2017 | Dec 31, 2017 | -$76.61M | – |
| FY2016 | Dec 31, 2016 | -$43.85M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$129.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$121.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$120.81M | – |
| Q3 FY2025 | Sep 30, 2025 | -$98.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$106.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$111.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$125.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$117.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$100.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$99.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$197.51M | – |
| Q3 FY2023 | Sep 30, 2023 | -$113.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$119.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$134.06M | – |
| Q4 FY2022 | Dec 31, 2022 | -$146.12M | – |
| Q3 FY2022 | Sep 30, 2022 | -$144.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$130.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -$123.34M | – |
| Q4 FY2021 | Dec 31, 2021 | -$98.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$107.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$97.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$107.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$91.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$74.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$54.62M | – |
| Q1 FY2020 | Mar 31, 2020 | -$34.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.48M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$23.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.39M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.21M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.70M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.62M | – |
| Q3 FY2017 | Sep 30, 2017 | -$28.68M | – |
See a number that looks wrong?